Allogene Therapeutics, Inc.
NASDAQ:ALLOBiotechnology
Healthcare
$0.70 +1.02%
+$0.02 today
- Market cap
- $241.11M
- Beta
- 0.46
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$0.72
52W Low $0.98High $4.46
Volume 10.55M
Average 10.19M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$149.25M
FY 2025 · Annual
Investing Cash Flow
$95.56M
FY 2025 · Annual
+26.3% YoYFinancing Cash Flow
$30.16M
FY 2025 · Annual
-74.2% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (257.01M) | (332.63M) | (327.27M) | (257.59M) | (190.89M) |
| Depreciation & Amortization | 10.45M | 14.3M | 14.2M | 13.64M | 12.36M |
| Deferred Income Tax | 10.4M | 8.08M | 0 | 443K | 0 |
| Stock-Based Compensation | 80.82M | 83.6M | 65.95M | 51.74M | 37.64M |
| Change in Working Capital | (32.09M) | 3.71M | (15.31M) | (24.8M) | (10.88M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (767K) | 4.87M | (7.5M) | (503K) | (1.23M) |
| Other Working Capital | (31.32M) | (1.16M) | (7.8M) | (24.3M) | (9.65M) |
| Other Non-Cash Items | 2.61M | 2.43M | 24.69M | 16.26M | 2.52M |
| Operating Cash Flow | (184.81M) | (220.52M) | (237.73M) | (200.3M) | (149.25M) |
| Capital Expenditures | (21.45M) | (5.19M) | (1.52M) | (694K) | (386K) |
| Acquisitions (Net) | (17.71M) | (111.35M) | 0 | 0 | 0 |
| Purchases of Investments | (525.58M) | (248.11M) | (438.63M) | (361.48M) | (138.26M) |
| Sales of Investments | 728.39M | 359.46M | 603.43M | 437.86M | 234.2M |
| Other Investing Activities | 0 | 111.35M | 0 | 0 | 0 |
| Investing Cash Flow | 163.66M | 106.16M | 163.29M | 75.69M | 95.56M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 11.96M | 2.95M | 91.11M | 114.4M | 23.25M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 4.58M | 2.28M | 6.91M |
| Financing Cash Flow | 11.96M | 2.95M | 95.7M | 116.68M | 30.16M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (9.19M) | (111.41M) | 21.25M | (7.94M) | (23.53M) |
| Free Cash Flow | (206.26M) | (225.71M) | (239.25M) | (200.99M) | (149.63M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$190.9M
+ D&A$12.4M
+ Stock-Based Comp$37.6M
+ Deferred Tax$0
- Working Capital-$10.9M
+ Other Non-Cash$2.5M
= Operating Cash Flow-$149.2M
- Capex-$386.0K
= Free Cash Flow-$149.6M
Analysis
FY2025 free cash flow is -$149.6M. FCF conversion is 78.4% of net income. Operating cash flow was -$149.2M, with capex of -$386.0K. The largest bridge item is Stock-Based Comp at $37.6M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 10, 2026 | |
| 10-Q | Quarterly report | Nov 6, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| SC 13G/A | SC 13G/A filing | Oct 27, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
Does ALLO generate free cash flow?
Allogene Therapeutics, Inc. (ALLO) generated -$149.63M of free cash flow in fiscal 2025.
How much operating cash flow does ALLO produce?
Operating cash flow was -$149.25M, before capital expenditures of $386,000.00.
Continue the stock analysis
Jump to another research area for this company.